Nuijen B - Search Results

1

Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.

Bins A, Mallo H, Sein J, van den Bogaard C, Nooijen W, Vyth-Dreese F, Nuijen B, de Gast GC, Haanen JB. Bins A, et al. Among authors: nuijen b. J Immunother. 2007 Feb-Mar;30(2):234-9. doi: 10.1097/01.cji.0000211333.06762.47. J Immunother. 2007. PMID: 17471170 Clinical Trial.

2

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.

Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B. Quaak SG, et al. Among authors: nuijen b. Eur J Pharm Biopharm. 2008 Oct;70(2):429-38. doi: 10.1016/j.ejpb.2008.05.002. Epub 2008 May 17. Eur J Pharm Biopharm. 2008. PMID: 18606527 Clinical Trial.

3

Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.

Quaak SG, Nuijen B, Haanen JB, Beijnen JH. Quaak SG, et al. Among authors: nuijen b. J Pharm Biomed Anal. 2009 Feb 20;49(2):282-8. doi: 10.1016/j.jpba.2008.11.011. Epub 2008 Nov 19. J Pharm Biomed Anal. 2009. PMID: 19111423

4

Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?

van den Berg JH, Quaak SG, Beijnen JH, Hennink WE, Storm G, Schumacher TN, Haanen JB, Nuijen B. van den Berg JH, et al. Among authors: nuijen b. Int J Pharm. 2010 May 5;390(1):32-6. doi: 10.1016/j.ijpharm.2009.06.031. Epub 2009 Jul 2. Int J Pharm. 2010. PMID: 19576975

5

DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

Quaak SG, van den Berg JH, Oosterhuis K, Beijnen JH, Haanen JB, Nuijen B. Quaak SG, et al. Among authors: nuijen b. J Control Release. 2009 Oct 15;139(2):153-9. doi: 10.1016/j.jconrel.2009.06.033. Epub 2009 Jul 4. J Control Release. 2009. PMID: 19580829

6

Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.

van den Berg JH, Oosterhuis K, Hennink WE, Storm G, van der Aa LJ, Engbersen JF, Haanen JB, Beijnen JH, Schumacher TN, Nuijen B. van den Berg JH, et al. Among authors: nuijen b. J Control Release. 2010 Jan 25;141(2):234-40. doi: 10.1016/j.jconrel.2009.09.005. Epub 2009 Sep 12. J Control Release. 2010. PMID: 19751778

7

Synthetic vehicles for DNA vaccination.

van den Berg JH, Nuijen B, Schumacher TN, Haanen JB, Storm G, Beijnen JH, Hennink WE. van den Berg JH, et al. Among authors: nuijen b. J Drug Target. 2010 Jan;18(1):1-14. doi: 10.3109/10611860903278023. J Drug Target. 2010. PMID: 19814658

8

Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.

Quaak SG, Haanen JB, Beijnen JH, Nuijen B. Quaak SG, et al. Among authors: nuijen b. AAPS PharmSciTech. 2010 Mar;11(1):344-50. doi: 10.1208/s12249-010-9391-2. Epub 2010 Mar 4. AAPS PharmSciTech. 2010. PMID: 20204715 Free PMC article.

9

DNA vaccination in oncology: current status, opportunities and perspectives.

van den Berg JH, Oosterhuis K, Beijnen JH, Nuijen B, Haanen JB. van den Berg JH, et al. Among authors: nuijen b. Curr Clin Pharmacol. 2010 Aug;5(3):218-25. doi: 10.2174/157488410791498734. Curr Clin Pharmacol. 2010. PMID: 20406167 Review.

10

Transposon leads to contamination of clinical pDNA vaccine.

van der Heijden I, Gomez-Eerland R, van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B. van der Heijden I, et al. Among authors: nuijen b. Vaccine. 2013 Jul 11;31(32):3274-80. doi: 10.1016/j.vaccine.2013.05.022. Epub 2013 May 23. Vaccine. 2013. PMID: 23707695

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page